Products
Umifenovir is available in Russia, among other countries, in tablet, capsule, and syrup form without a doctor’s prescription (Arbidol). It was developed in the Soviet Union in the 1970s. The drug is not approved in the United States, Europe, and Switzerland.
Structure and properties
Umifenovir (C22H25BrN2O3S, Mr = 477.4 g/mol) is a brominated indole derivative.
Effects
Umifenovir (ATC J05AX13) has antiviral and immunomodulatory properties with a broad spectrum of activity against various enveloped and non-enveloped viruses. The effects are based on the inhibition of the fusion of the virus with the cell membrane. This prevents the entry of viruses into the cells. Furthermore, it also inhibits fusion with the membrane of endosomes and is thought to have immunostimulatory effects. The half-life is 17 to 21 hours.
Indications
For the prevention and treatment of influenza (flu). The SmPC lists other indications for use. These include:
- SARS
- Secondary immunodeficiency
- Recurrent herpes infections
- RSV (respiratory syncytial virus).
- Rotavirus infection
In 2020, umifenovir was studied for the treatment of viral respiratory disease Covid-19.
Dosage
According to the SmPC. The drugs are administered perorally and before meals. Dosage depends on the indication.
Contraindications
- Hypersensitivity
- Children under 3 years
Full precautions can be found in the drug label.
Interactions
Umifenovir is metabolized in the liver.
Adverse effects
Umifenovir is considered well tolerated according to the SmPC. Possible adverse effects include allergic reactions.
